The business of covid19 and illicit drugs is death; the business of Leronlimab is to prevent that. I find it odd that the Cytodyn severe/critical covid19 study with results strongly telegraphing an 85% reduction in mortality for the critical sub population should have death as a side effect seriously called into question. I find it equally odd that the FDA would stare right down the barrel of that data and with a straight face say “but, but, but…it’s a sub population you didn’t separate out on your protocol for separate analysis…”, all the while the planet is staring down death and looking for some hope…nearly 7 million people died to uphold strict scientific rigor and the failure to use some common sense judgement under EUA rules meant that all these people were effectively sent to their death.

Imagine if the FDA was around during the global plague epidemic and made that same argument while 75-200 million people died.